Zynerba Pharmaceuticals, Inc. (ZYNE) is a publicly traded company in the Unknown sector. Across all available filings, 16 corporate insiders have executed 147 transactions totaling $2.6M, demonstrating a bullish sentiment with $2.2M in net insider flow. The most recent transaction on Oct 10, 2023 involved a transaction of 47,824 shares valued at $0.
No significant insider buying has been recorded for ZYNE in the recent period.
No significant insider selling has been recorded for ZYNE in the recent period.
Based on recent SEC filings, insider sentiment for ZYNE is bullish with an Insider Alignment Score of 93/100 and a net flow of $2.2M. Insiders are accumulating shares, which historically signals confidence in the company's future performance.
Insider trading at Zynerba Pharmaceuticals, Inc. (ZYNE) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 16 insiders are actively trading ZYNE stock, having executed 147 transactions in the past 90 days. The most active insider is Michael Rapp (Executive), who has made 10 transactions totaling $1.6M.
Get notified when executives and directors at ZYNE file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Oct 10, 2023 | L. Kisner Daniel | Executive | Tender | 47,824 | $N/A | $0 | |
| Oct 10, 2023 | L. Kisner Daniel | Executive | Tender | 27,954 | $N/A | $0 | |
| Oct 10, 2023 | Anido Armando | Executive | Tender | 13,297 | $N/A | $0 | |
| Oct 10, 2023 | Anido Armando | Executive | Tender | 26,595 | $N/A | $0 | |
| Oct 10, 2023 | Anido Armando | Executive | Tender | 610,000 | $N/A | $0 | |
| Oct 10, 2023 | Anido Armando | Executive | Award | 240,000 | $N/A | $0 | |
| Oct 10, 2023 | Anido Armando | Executive | Tender | 566,722 | $N/A | $0 | |
| Oct 10, 2023 | I. Moch Kenneth | Executive | Tender | 47,824 | $N/A | $0 | |
| Oct 10, 2023 | I. Moch Kenneth | Executive | Tender | 27,954 | $N/A | $0 | |
| Oct 10, 2023 | P. Butler John | Executive | Tender | 47,824 | $N/A | $0 | |
| Oct 10, 2023 | P. Butler John | Executive | Tender | 32,941 | $N/A | $0 | |
| Oct 10, 2023 | P. Parker Albert | Executive | Tender | 33,685 | $N/A | $0 | |
| Oct 10, 2023 | P. Parker Albert | Executive | Tender | 278,333 | $N/A | $0 | |
| Oct 10, 2023 | P. Parker Albert | Executive | Award | 85,000 | $N/A | $0 | |
| Oct 10, 2023 | D. Cooper Warren | Executive | Tender | 27,954 | $N/A | $0 |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Purchase(P) | 20 | $2.4M | 89.0% |
Sale(S) | 27 | $185.7K | 6.9% |
Exercise(M) | 1 | $63.5K | 2.4% |
Payment(F) | 10 | $46.4K | 1.7% |
Tender(U) | 26 | $0 | 0.0% |
Award(A) | 59 | $0 | 0.0% |
Other(J) | 1 | $0 | 0.0% |
Conversion(C) | 3 | $0 | 0.0% |
Insiders at Zynerba Pharmaceuticals, Inc. are accumulating shares at an accelerated pace. With 16 insiders making 147 transactions totaling $2.4M in purchases versus $185.7K in sales, the net buying activity of $2.2M signals strong executive confidence. Michael Rapp (Executive) leads the buying activity with $1.6M in transactions across all time.